Royal Jubilee Hospital, Victoria, BC, Canada.
Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada.
Mol Genet Genomic Med. 2020 Apr;8(4):e1151. doi: 10.1002/mgg3.1151. Epub 2020 Jan 28.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare inherited arrhythmia syndrome characterized by adrenergically driven ventricular arrhythmia predominantly caused by pathogenic variants in the cardiac ryanodine receptor (RyR2). We describe a novel variant associated with cardiac arrest in a mother and daughter.
Initial sequencing of the RYR2 gene identified a novel variant (c.527G > T, p.R176L) in the index case (the mother), and her daughter. Structural analysis demonstrated the variant was located within the N-terminal domain of RyR2, likely leading to a gain-of-function effect facilitating enhanced calcium ion release. Four generation cascade genetic and clinical screening was carried out.
Thirty-eight p.R176L variant carriers were identified of 94 family members with genetic testing, and 108 family members had clinical evaluations. Twelve carriers were symptomatic with previous syncope and 2 additional survivors of cardiac arrest were identified. Thirty-two had clinical features suggestive of CPVT. Of 52 noncarriers, 11 had experienced previous syncope with none exhibiting any clinical features of CPVT. A documented arrhythmic event rate of 2.89/1000 person-years across all carriers was calculated.
The substantial variability in phenotype and the lower than previously reported penetrance is illustrative of the importance of exploring family variants beyond first-degree relatives.
儿茶酚胺多形性室性心动过速(CPVT)是一种罕见的遗传性心律失常综合征,其特征为肾上腺素能驱动的室性心律失常,主要由心脏兰尼碱受体(RyR2)的致病性变异引起。我们描述了一例与母女心搏骤停相关的新型变异。
最初对 RYR2 基因进行测序,在索引病例(母亲)及其女儿中发现了一种新型变异(c.527G>T,p.R176L)。结构分析表明,该变异位于 RyR2 的 N 端结构域内,可能导致获得性功能增强,促进钙离子释放。进行了四代级联遗传和临床筛查。
在进行基因检测的 94 名家庭成员中,发现了 38 名 p.R176L 变异携带者,对 108 名家庭成员进行了临床评估。12 名携带者有症状,以前曾出现过晕厥,另外还有 2 名幸存者发生了心搏骤停。32 名有 CPVT 的临床特征。在 52 名非携带者中,有 11 人以前曾出现过晕厥,但没有人表现出 CPVT 的任何临床特征。所有携带者的心律失常事件发生率为 2.89/1000 人年。
表型的显著变异性和低于先前报道的外显率表明,探索家族变异不仅仅局限于一级亲属是很重要的。